以下文章来源于赛业生物订阅号 ，作者小赛 赛业生物订阅号 . 分享生命科学领域的前沿资讯、解读行业动态、讲解实用的学科知识、实验方法和技巧。 国自然 （NSFC） 的资助方向是学科发展的晴雨表。2026年申报在即，洞察热点趋势对于课题设计至关重 要。基于对历年资助项目与前沿发表的综合分析，我们猜测，以下几个热点领域，在新的一年将继续保持高 热度和高竞争力。 ➢ 核心机制类： 免疫调控 （巨噬细胞极化、中性粒细胞、T细胞耗竭） 、线粒体功能与稳态、新型细胞死 亡 （铁死亡、焦亡） 、代谢重编程 （糖酵解、乳酸化） 、蛋白质翻译后修饰 （泛素化、SUMO化、组蛋 白修饰） ； ➢前沿交叉类： 表观转录组学 （RNA修饰，如m6A、m7G） 、细胞间通讯 （外泌体） 、宿 主-微生物互作 （肠道菌群） 、干细胞与再生医学； ➢关键技术类： 单细胞与空间多组学、类器官与疾病模型、人工智能/机器学习驱动的靶点发现与数据分析 这些方向并非孤立存在，例如铁死亡不仅是一种程序性细胞死亡机制，更与免疫代谢、蛋白质修饰网络和 RNA表观调控紧密相连；外泌体则作为载体，跨界调控着肿瘤免疫与神经疾病中的细胞命运……因此， 从单 一热 ...

Core Viewpoint - Jiangxi Jindalai Environmental Protection Co., Ltd. is making significant moves towards diversification by investing in the healthcare sector, specifically in stem cell technology and medical robotics, to optimize its industrial structure and cultivate new profit growth points [2][3][21]. Investment in Healthcare - On December 19, Jindalai announced an investment of 280 million yuan in Yunnan Jici Medical Technology Co., Ltd., acquiring a 34% stake, making it the second-largest shareholder [2][21]. - On December 21, the company announced an additional investment of 30 million yuan in Beijing Zhongke Hongtai Medical Technology Co., Ltd., acquiring a 10% stake [3][21]. - Both investments target the "big health industry," with Jici Medical focusing on proprietary stem cell technology and Zhongke Hongtai excelling in medical artificial intelligence [3][21]. Rationale for Investment - Jindalai aims to respond to national calls for investment in biomanufacturing and healthcare sectors, enhancing its risk resistance and creating new profit avenues [3][21]. - The company believes that the aging population and the maturation of the industry in China present ample investment opportunities in the big health sector [3][21]. Financial Overview of Jici Medical - As of September 30, Jici Medical reported total assets of 10.01 million yuan, with revenues and net profits of 11.23 million yuan and 1.15 million yuan, respectively, for the first nine months of 2025 [6][26]. - Despite not being particularly strong financially, Jici Medical's ability to generate initial self-sustaining revenue is notable in the capital-intensive biomanufacturing sector [6][26]. Financial Overview of Zhongke Hongtai - Zhongke Hongtai reported total assets of 61.58 million yuan and a net loss of 5.51 million yuan for the first nine months of 2025 [10][31]. - The company is recognized for its innovative medical robotics and has completed 16 clinical trials for its products, which are currently in the regulatory approval process [10][31]. Jindalai's Current Position - Jindalai has a strong financial position, with a debt ratio of only 10.2% and cash reserves exceeding 1.898 billion yuan, allowing it to fund these investments entirely with its own capital [12][33]. - However, the company has experienced a decline in its main business, with a 23.5% drop in total revenue and a 30.14% decrease in net profit for the first nine months of 2025 [13][33]. Strategic Shift - The investments in Jici Medical and Zhongke Hongtai mark Jindalai's formal entry into the biomanufacturing and big health sectors, aligning with national policies that support these industries as emerging growth areas [16][36]. - The company is part of a broader trend among environmental firms diversifying into non-environmental sectors, with nearly half of the listed environmental companies exploring such opportunities [17][38].

Core Insights - Fosun Health and Fakeeh Care Group signed a strategic cooperation memorandum in Jeddah, Saudi Arabia, focusing on four core areas: specialty construction and academic exchange, IT and digital hospital solutions, preventive medicine and wearable devices, and stem cell and regenerative medicine [1][2] Group 1: Strategic Cooperation - The cooperation aims to establish a regular academic exchange mechanism in disciplines such as oncology, cardiovascular, and pediatrics, utilizing remote consultations, personnel visits, and thematic seminars to enhance clinical capabilities and hospital management experience [1] - Both parties will collaborate on digital hospital upgrades and local practices, leveraging Fosun Health's mature smart hospital management system to explore smart healthcare solutions tailored to the Gulf Cooperation Council (GCC) market [1][2] Group 2: Innovation and Research - A new integrated chronic disease management service model will be developed, combining device monitoring, AI early warning, and insurance payment [1] - The partnership will also focus on building a research transformation platform in the field of stem cell and regenerative medicine to support the localization strategy of biotechnology in Saudi Arabia [1][2] Group 3: Market Potential and Collaboration - This collaboration marks a significant step in Fosun Health's internationalization strategy in the Middle East and aims to deepen strategic synergy with Fakeeh Care Group [2] - Both companies will leverage their complementary resources to accelerate medical technology sharing, joint talent cultivation, and industrial innovation transformation [2]

全球首个同种异体人工再生血小板临床研究在沪取得成功，首批3例患者输注后证实安全性良好。9月5日，智通财 经记者从国家儿童医学中心、上海交通大学医学院附属上海儿童医学中心获悉这一消息。 上述医院透露，该院近日成功完成全球首项同种异体人工再生血小板临床输注研究，这标志着我国在干细胞与再 生医学临床转化领域取得进一步突破。该研究由上海儿童医学中心血液科沈树红教授团队牵头，联合肿瘤外科、 心胸外科等多学科团队协作，他们成功为3例急性白血病、再生障碍性贫血及复杂先心病术后患者完成"人诱导多 能干细胞来源血小板（iPLT）"输注，初步证实其良好的安全性和耐受性，为临床解决血小板供应短缺及输注风险 带来全新希望。 截至目前，该研究已顺利完成3例受试者的输注治疗，涵盖急性白血病、再生障碍性贫血及法洛四联征术后等多种 临床类型。研究过程中未发生任何与研究药物相关的严重不良事件或剂量限制性毒性，初步验证了"人诱导多能干 细胞来源血小板（iPLT）"在人体应用中的良好安全性。 上海儿童医学中心临床研究管理中心主任孙心岩表示，人工再生血小板技术的成功转化和初步安全性验证，为应 对血小板供应短缺和安全性问题提供了全新方向。尽管目前仍属 ...

Core Viewpoint - The Shandong Provincial Department of Science and Technology has approved the "Stem Cell sEV for Regenerative Repair of Key Organs and Clinical Industrial Transformation" project from Jinan Medical University Affiliated Hospital, marking a significant breakthrough in the hospital's pharmaceutical product development and recognition at the provincial level [1][3]. Group 1: Project Approval and Significance - The project is part of the Shandong Provincial Key R&D Program (Competitive Innovation Platform), aimed at gathering innovative resources and tackling key technologies [3]. - The approval signifies Jinan Medical University Affiliated Hospital's strong development momentum in cell therapy research and clinical industrial transformation [3]. Group 2: Project Focus and Goals - The project, led by Professor Zhang Bin, will focus on key scientific issues and industrial bottlenecks related to stem cell extracellular vesicles (sEV) in tissue regeneration and repair [3]. - The aim is to analyze the secretion regulation mechanisms of sEV, optimize engineering modification technologies, and establish standardized production systems, creating a complete industrial chain from basic research to clinical transformation [3]. Group 3: Future Development and Impact - The establishment and operation of this platform will significantly enhance innovation in the field of stem cells and regenerative medicine, improving the hospital's core competitiveness in biotherapy technology and product development [4]. - The hospital plans to leverage this opportunity to advance platform construction, focus on core technology breakthroughs, deepen industry-academia-research cooperation, and accelerate the transformation of research outcomes [4].